Physician profile
Rakesh Patel
NPI 1720109598
$6,650.13
in general payments reported to CMS, 2019-2025
35 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $305 · 2021: $618 · 2022: $1,268 · 2023: $1,116 · 2024: $1,316 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,627.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $623.50 | 2020-2025 | Repatha, Repatha |
| Medtronic, INC. | $606.97 | 2021-2025 | Corevalve Evolut R, Linq II |
| Novartis Pharmaceuticals Corporation | $498.37 | 2019-2025 | |
| Boston Scientific Corporation | $496.54 | 2019-2025 | Watchman Flx, Avvigo Guidance System, Cds - Mct/Cem Monitoring |
| Shockwave Medical, INC | $471.85 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biotronik INC. | $390.24 | 2022-2025 | Biomonitor, Renamic Neo, Acticor 7 Vr-T Dx |
| Cvrx, INC. | $316.02 | 2022-2025 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $308.07 | 2021-2025 | Optimizer, Optimizer |
| Merck Sharp & Dohme LLC | $256.54 | 2021-2024 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $225.11 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $222.35 | 2019-2024 | Farxiga |
| Cardiovascular Systems INC. | $209.80 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $203.24 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $201.44 | 2022-2025 | Impella |
| Janssen Pharmaceuticals, INC | $176.40 | 2020-2024 | Xarelto |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.